On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will most likely never ever disappear and a vaccine will not quit it absolutely. He also mentioned that ministers and specialists must quit ‘over-promising’ and be realistic about the prospects of a vaccine and the most likely timeline of a single, unlikely ahead of spring subsequent year.
He then echoed his earlier warnings and these of his colleague Professor Chris Whitty that the COVID-19 fight will be a extended one particular, and it will be with us for very good.
So, from this really should we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there had been a single therapy that:
could cease the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in circumstances where patients created secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug already verified as protected
was simple to make, scalable at the level expected to make a distinction in the pandemic and was cost efficient, then wouldn’t that be a thing we ought to all be having excited about?
Certainly although no such ‘silver bullet’ game altering therapy exists? Immediately after all, the only therapies we hear about for COVID are these which President Trump took, which were either incredibly new, high priced and experimental or have a quite narrow application to a particular aspect of the illness.
Properly, you heard it here initial – such a ‘silver bullet’ therapy does exist right now. It’s referred to as Nylexa®, from the smaller UK biotech corporation NovaBiotics Ltd. It’s active ingredients have been safely made use of in medicines that treat unrelated conditions for over 30 years.
NovaBiotics found Nylexa’s possible rewards in COVID-19 following a decade of investigation in tricky to treat, drug-resistant infections, such as the complex chest infections and inflammation linked with cystic fibrosis (CF) lung disease. In March they applied for a £1m grant from Innovate UK (representing the government) to begin clinical studies. That grant was ultimately awarded earlier this month, and the government are now taking into consideration whether or not to include Nylexa on two separate NHS platform research.
But why, I hear you ask, if this is so superior have we not heard about it ahead of? Why are the government and the press not shouting about this from the rooftops? Why is dr dan stock not becoming demanded by clinicians desperate for productive remedies for their sufferers?
I’m afraid to say, it all boils down to funds. Compact biotech companies locate it tough to get focus as they don’t have the sources out there to their bigger much better funded rivals. The names we study about frequently when it comes to ground breaking new treatments are invariably significant multi-national pharmaceutical organizations with deep pockets and big budgets to promote their own particular wares. They make confident their drugs get the needed interest. NovaBiotics is a small private organization funded by a group of loyal and supportive shareholders so regrettably never have the resources to compete for interest with the major boys.
Which is why this predicament is so frustrating. In mitigating the health consequences of contracting COVID-19, Nylexa® could raise public confidence of living with the virus for the longer term and potentially let a higher degree of normality to return to the way in which we live, benefiting the economy directly in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. However having folks in positions of influence to take notice amongst all the other folks competing for their consideration is very complicated indeed.
It is reported that there are thousands of prospective COVID-19 remedies in clinical trials across the world. I would challenge any person to show me one which has the identical prospective for optimistic effect as Nylexa®, but this is not currently element of any trial, regardless of its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials instantly. The sooner it gets tested, the sooner it can be employed to help sort out the mess the pandemic has triggered to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology business focused on the design and improvement of very first-in-class therapies for difficult-to-treat, medically unmet infectiousdiseases triggered by bacteria and fungi and respiratory circumstances like cystic fibrosis and COVID-19.
A major innovator in the anti-infectives space, the Company’s robust technology and business model has been validated by way of profitable development, from concept to late stage clinical development, of its most sophisticated product candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, high-value drug candidates like NP339 (Division of Overall health and Social Care funded programme) for life threatening, drug resistant invasive fungal illness and NP432 for multi- drug resistant bacterial infections.